Ex Vivo Fluorescence Confocal Microscopy (FCM) Ensures Representative Tissue in Prostate Cancer Biobanking: A Feasibility Study.
biobanking
cryoasservation
digital medicine
fluorescence confocal microscopy (FCM)
prostate cancer (PCa)
targeted sampling
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
11 Oct 2022
11 Oct 2022
Historique:
received:
27
08
2022
revised:
24
09
2022
accepted:
30
09
2022
entrez:
27
10
2022
pubmed:
28
10
2022
medline:
29
10
2022
Statut:
epublish
Résumé
Biobanking of prostate carcinoma is particularly challenging due to the actual cancer within the organ often without clear margins. Frozen sections are to date the only way to examine the biobank material for its tumor content. We used ex vivo fluorescence confocal microscopy (FCM) to analyze biobank samples prior to cryoasservation. 127 punch biopsies were acquired from prostatectomy-specimens from 40 patients. These biopsies were analyzed with a Vivascope 2500-G4 prior to their transfer to the biobank. In difficult cases, larger samples of the prostatectomy specimens were FCM scanned in order to locate tumor foci. After patient acquisition, all samples were taken from the biobank and analyzed. We compared the results of the FCM examinations with the results of conventional histology and measured the DNA content. With upstream FCM, the tumor content of biobank samples could be determined with high confidence. The detection rate of representative biobank samples was increased due to the rapid feedback. The biobank samples were suitable for further molecular analysis. FCM allows for the first time lossless microscopic analysis of biobank samples prior to their cryoasservation and guarantees representative tumor and normal tissue for further molecular analysis.
Sections du résumé
BACKGROUND
BACKGROUND
Biobanking of prostate carcinoma is particularly challenging due to the actual cancer within the organ often without clear margins. Frozen sections are to date the only way to examine the biobank material for its tumor content. We used ex vivo fluorescence confocal microscopy (FCM) to analyze biobank samples prior to cryoasservation.
METHODS
METHODS
127 punch biopsies were acquired from prostatectomy-specimens from 40 patients. These biopsies were analyzed with a Vivascope 2500-G4 prior to their transfer to the biobank. In difficult cases, larger samples of the prostatectomy specimens were FCM scanned in order to locate tumor foci. After patient acquisition, all samples were taken from the biobank and analyzed. We compared the results of the FCM examinations with the results of conventional histology and measured the DNA content.
RESULTS
RESULTS
With upstream FCM, the tumor content of biobank samples could be determined with high confidence. The detection rate of representative biobank samples was increased due to the rapid feedback. The biobank samples were suitable for further molecular analysis.
CONCLUSION
CONCLUSIONS
FCM allows for the first time lossless microscopic analysis of biobank samples prior to their cryoasservation and guarantees representative tumor and normal tissue for further molecular analysis.
Identifiants
pubmed: 36292970
pii: ijms232012103
doi: 10.3390/ijms232012103
pmc: PMC9603154
pii:
doi:
Substances chimiques
DNA
9007-49-2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
J Transl Med. 2017 Nov 7;15(1):229
pubmed: 29116016
Prostate. 2019 May;79(7):768-777
pubmed: 30807665
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
Nat Rev Urol. 2021 Feb;18(2):79-92
pubmed: 33328650
Diagn Mol Pathol. 2012 Jun;21(2):61-8
pubmed: 22555088
Lancet Digit Health. 2020 Aug;2(8):e407-e416
pubmed: 33328045
J Clin Pathol. 2012 Dec;65(12):1057-61
pubmed: 22872704
Prostate. 1994 Nov;25(5):274-9
pubmed: 7526353
Comput Math Methods Med. 2022 Jun 28;2022:8123643
pubmed: 35799629
J Cell Sci. 2016 Dec 15;129(24):4622-4632
pubmed: 27875278
Eur Urol Focus. 2021 Nov;7(6):1254-1259
pubmed: 32912840
J Clin Invest. 2013 Nov;123(11):4918-22
pubmed: 24135135
Diagnostics (Basel). 2022 Jan 21;12(2):
pubmed: 35204368
J Microsc. 2009 May;234(2):124-9
pubmed: 19397741
Arch Pathol Lab Med. 2006 Mar;130(3):303-17
pubmed: 16519557
N Engl J Med. 2018 Feb 15;378(7):645-657
pubmed: 29412780
Adv Anat Pathol. 2016 May;23(3):159-69
pubmed: 27058244
Diagn Pathol. 2022 Jun 28;17(1):55
pubmed: 35765032
Anticancer Res. 2018 Jan;38(1):481-489
pubmed: 29277813
J Transl Med. 2019 May 22;17(1):172
pubmed: 31118074
BMC Med Inform Decis Mak. 2010 Nov 15;10:71
pubmed: 21078179
Eur Urol. 2015 Mar;67(3):569-76
pubmed: 25257029
Front Oncol. 2019 Sep 24;9:925
pubmed: 31612102
Nature. 2015 Apr 16;520(7547):353-357
pubmed: 25830880
Virchows Arch. 2020 Apr;476(4):511-520
pubmed: 31907606
Front Oncol. 2018 Oct 02;8:400
pubmed: 30333957
Int Rev Cytol. 1967;21:141-202
pubmed: 5338238
Eur Urol Oncol. 2021 Oct;4(5):784-791
pubmed: 32952095
Cancers (Basel). 2022 Jan 25;14(3):
pubmed: 35158859
Prostate. 2013 Jan;73(2):194-202
pubmed: 22806573
Transl Androl Urol. 2021 Mar;10(3):1569-1580
pubmed: 33850791
Prostate. 2017 Mar;77(4):396-405
pubmed: 27862105
J Transl Med. 2011 Jul 26;9:121
pubmed: 21791045
Cancers (Basel). 2021 Nov 13;13(22):
pubmed: 34830839
J Biomed Opt. 2009 May-Jun;14(3):034050
pubmed: 19566342
J Clin Pathol. 2005 May;58(5):504-8
pubmed: 15858122
Int J Surg Pathol. 2009 Jun;17(3):238-43
pubmed: 18508841
IARC Monogr Eval Carcinog Risk Chem Man. 1978 Jan;16:145-52
pubmed: 640661
Eur J Surg Oncol. 2007 Apr;33(3):352-7
pubmed: 17175129
Hum Pathol. 2010 Jun;41(6):781-93
pubmed: 20466122
Nat Commun. 2020 Feb 13;11(1):837
pubmed: 32054861
Biometrics. 1977 Mar;33(1):159-74
pubmed: 843571
Cancers (Basel). 2021 Aug 30;13(17):
pubmed: 34503192
Quant Imaging Med Surg. 2021 Apr;11(4):1322-1332
pubmed: 33816171
J Virol Methods. 2003 Dec;114(1):29-35
pubmed: 14599676